In a new study, researchers found no association between treatment with GLP-1 Receptor Agonists like Ozempic and Wegovy and increased risk of adverse psychiatric events.
Popular diabetes and weight loss drugs like Ozempic and Wegovy do not increase the risk of depression, anxiety or suicidal ideation, a new study finds.
In fact, researchers say treatment with GLP-1 receptor agonists may actually help improve the mental health of patients.
The researchers reviewed data from 80 clinical trials that compared GLP-1 receptor agonists to placebo in more than 107,000 adults with obesity and/or diabetes. Trials were included if they reported adverse psychiatric events or changes in psychiatric symptoms.
The results showed treatment with GLP-1 receptor agonists was not associated with worsening depression or other adverse psychiatric events.
But they were associated with reduced emotional eating, increased eating restraint and a better health-related quality of life.
The authors say these findings are reassuring for patients and “suggest that GLP1-RA treatment contributes to both physical and emotional well-being.”
Source: JAMA Psychiatry
Author Affiliations: Guy’s and St Thomas’ NHS Foundation Trust, King’s College London, Imperial College London, University of Oxford, Oxford Health NHS Foundation Trust, King’s Health Partners London, Maudsley NHS Foundation Trust, Keio University School of Medicine, University of Edinburgh
Copyright © 2025 HealthDay. All rights reserved.
Leave a Reply